Beyond Cancer announced key data demonstrating the efficacy of Low Volume Ultra-High Concentration Nitric Oxide, LV UNO, when combined with immune checkpoint inhibitors, which were presented in two posters at the Society for Immunotherapy of Cancer, SITC, Annual Meeting 2024. These studies found that: LV UNO in combination with anti-rPD-L1 resulted in prolonged survival and doubled the tumor growth inhibition rate in MAT B III tumor bearing rats compared to anti-rPD-L1 alone; LV UNO compares favorably to HV UNO administration in reducing tumor volumes in combination with anti-mPD-1 in CT26 BALB/c mice; and Increased nitro-tyrosine staining in LV UNO treated tumors indicates an improved distribution of UNO in the tumor leading to potentially improved outcomes and an enhanced safety profile
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Is XAIR a Buy, Before Earnings?
- Beyond Air files to sell 81.7M shares of common stock for holders
- Beyond Air announces strategic partnership with Healthcare Links
- Costco reports Q4 earnings beat, Cassava to settle SEC charges: Morning Buzz
- Beyond Air to sell 40.39M shares at 51c in private placement